Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$8.10 USD
+0.30 (3.85%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Rapt Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 4 | 5 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 2 | 4 | 5 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 127 | 87 | 73 | 58 | 44 |
Income After Depreciation & Amortization | -127 | -86 | -69 | -53 | -44 |
Non-Operating Income | 10 | 2 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -117 | -84 | -69 | -52 | -42 |
Income Taxes | 0 | 0 | 0 | 1 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -117 | -84 | -69 | -53 | -43 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -117 | -84 | -69 | -53 | -43 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -132 | -85 | -67 | -52 | -42 |
Depreciation & Amortization (Cash Flow) | -5 | 1 | 2 | 2 | 1 |
Income After Depreciation & Amortization | -127 | -86 | -69 | -53 | -44 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.34 | 32.54 | 27.39 | 24.13 | 4.35 |
Diluted EPS Before Non-Recurring Items | -3.05 | -2.58 | -2.53 | -2.19 | -9.89 |
Diluted Net EPS (GAAP) | -3.05 | -2.58 | -2.53 | -2.19 | -9.89 |
Fiscal Year end for Rapt Therapeutics falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 33.21 | 33.92 | 28.36 | 31.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -33.21 | -33.92 | -28.36 | -31.56 |
Non-Operating Income | NA | 2.34 | 2.55 | 3.08 | 2.29 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -30.88 | -31.37 | -25.28 | -29.27 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -30.88 | -31.37 | -25.28 | -29.27 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -30.88 | -31.37 | -25.28 | -29.27 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.38 | 38.36 | 38.33 | 38.28 |
Diluted EPS Before Non-Recurring Items | NA | -0.80 | -0.82 | -0.66 | -0.76 |
Diluted Net EPS (GAAP) | NA | -0.81 | -0.82 | -0.66 | -0.76 |